Table 1.
Baseline demographic and clinical characteristics, lung function measures, and radiographic measures
| Cyclophosphamide (n = 47) | Mycophenolate Mofetil (n = 50) | Total (N = 97) | |
|---|---|---|---|
| Age, yr | 51.5 (9.2) | 51.7 (9.0) | 51.6 (9.0) |
| Female sex | 8 (17.0%) | 17 (34.0%) | 25 (25.8%) |
| Race | |||
| White | 30 (63.8%) | 35 (70%) | 65 (67.0%) |
| African American | 12 (25.5%) | 11 (22%) | 23 (23.7%) |
| Asian | 2 (4.3%) | 4 (8%) | 6 (6.2%) |
| Native American | 1 (2.1%) | 0 (0%) | 1 (1.0%) |
| Other | 2 (4.3%) | 0 (0%) | 2 (2.1%) |
| Hispanic ethnicity | 7 (14.9%) | 5 (8.0%) | 11 (11.3%) |
| FVC, % predicted | 66.6 (10.0) | 66.0 (7.8) | 66.3 (8.9) |
| FEV1, % predicted | 69.5 (9.5) | 68.0% (9.3) | 68.7 (9.4) |
| FEV1/FVC percent | 82.8 (5.1) | 81.5 (5.6) | 82.1 (5.4) |
| DlCO, % predicted | 55.4 (14.8) | 54.6 (11.4) | 55.0 (13.1) |
| DlCO/Va ratio | 3.9 (0.8) | 3.9 (0.7) | 3.9 (0.8) |
| TLC, L | 3.6 (0.93) | 3.8 (0.92) | 3.7 (0.9) |
| RV, L | 1.2 (0.51) | 1.3 (0.50) | 1.2 (0.51) |
| mRSS | 11.1 (8.2) | 16.4 (9.9) | 13.8 (9.5) |
| BDI* | 7.3 (2.3) | 7.5 (2.2) | 7.5 (2.2) |
Definition of abbreviations: BDI = Baseline Dyspnea Index, on which the score ranges from 1 to 12, with 1 indicating the most impairment; DlCO = diffusing capacity of the lung for carbon monoxide; DlCO/Va = diffusing capacity of the lung for carbon monoxide adjusted for alveolar volume; FEV1 = forced expiration volume in 1 second; FVC = forced vital capacity; mRSS = modified Rodnan skin score ranging from 0 to 51; RV = residual volume; TLC = total lung capacity.
Continuous data are expressed as mean (standard deviation). Categorical data are expressed as frequency (percent).
*
n = 45 for cyclophosphamide and n = 48 for mycophenolate mofetil.